DC4U
Breukelen
About DC4U
DC4U is a life science company that develops technologies enabling steering the human immune response. Its core expertise is the immunological application of glycobiology. Based on this knowledge a platform technology (GlycoDC) was developed which can modulate the immune system and can be applied to antigen based therapeutics and products. Its GlycoDCTM technology can either potentiate or suppress the immune system via specific targeting of dendritic cells by glycan modified antigen conjugates.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $7.7M
- Last round: Grant (Oct 2022)
- Website: dc4u-technologies.nl
- Phone: +31 6 55 816 195
Industries & Categories
Biotechnology, Life Science, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/dc4u-11898 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.